Interpace Biosciences Inc EBITDA margin
What is the EBITDA margin of Interpace Biosciences Inc?
The EBITDA margin of Interpace Biosciences Inc is -88.65%
What is the definition of EBITDA margin?
EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.
ttm (trailing twelve months)
EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.
EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.
EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.
EBITDA margin of companies in the Health Care sector on NASDAQ compared to Interpace Biosciences Inc
What does Interpace Biosciences Inc do?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
Companies with ebitda margin similar to Interpace Biosciences Inc
- Zhongtian International has EBITDA margin of -89.61%
- Imperium Global has EBITDA margin of -89.60%
- Cashwerkz has EBITDA margin of -89.43%
- Ur- has EBITDA margin of -89.04%
- PointsBet has EBITDA margin of -88.99%
- PointsBet has EBITDA margin of -88.99%
- Interpace Biosciences Inc has EBITDA margin of -88.65%
- LION E-Mobility AG has EBITDA margin of -88.63%
- Amatheon Agri N.V has EBITDA margin of -88.58%
- Flow Beverage has EBITDA margin of -88.50%
- SNDL Inc has EBITDA margin of -88.46%
- The Supreme Cannabis Co has EBITDA margin of -88.42%
- The Supreme Cannabis has EBITDA margin of -88.42%